Thank you, Mr. Chair.
I thank the witnesses for being here with us today.
Mr. Gagnon, it seems to me that there are two separate issues here that are being mixed up. I would like some clarifications on some of the things you said in your presentation.
The cost of medication is much higher in Canada than in Europe. However, investing in research and development is also at issue. The cost of medication is linked to the factors you have just spoken of, but investment in research and development is also related to other factors. However, in your presentation you did establish a correlation between those two.
Under the free trade agreement with Europe, are these two different things or should we consider them together?